MKM. I. Koreshkina

M. I. Koreshkina

*This is an algorithmically generated author record based on publicly available information.

M. I. Koreshkina has a total of 60 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Global practical recommendations from the International Headache Society for the treatment of migraine attacks: an adapted Russian-language version

    by V. V. Osipova, M. A. Vinokurov, A. R. Artemenko, E. R. Lebedeva, A. V. Sergeev, Yu. E. Azimova, A. V. Amelin, L. R. Akhmadeeva, O. B. Doronina, E. V. Ekusheva, et al.

    The article was prepared by experts of the Russian Headache Society (RHS) and represents an adapted Russian-language version of the International Headache Society (IHS) Global practice recommendations for the treatment of migraine attacks, developed taking into account data from systematic reviews, meta-analyses and consensus documents. The recommendations have two levels: optimal – for countries and regions where most medicines are available, and basic – for regions with limited treatment options. Treatment algorithms using non-steroidal anti-inflammatory drugs, triptans, and gepants are presented, along with specific considerations for their use in special patient groups: pregnant women, the elderly, and patients with cardiovascular diseases. Medicines not registered in the Russian Federation and available alternatives are indicated. The adapted recommendations take into account the Russian specifics of drug availability and the clinical recommendations of the Ministry of Health of Russia. Compliance with the recommendations will improve the quality of care for patients with migraine in the Russian Federation.

  • Open Access

    Experience of using Russian rizatriptan 10 mg tablets in routine clinical practice: results of a multicenter post-registration observational study “OPYT”

    by G. R. Tabeeva, A. B. Danilov, M. I. Koreshkina, E. Z. Yakupov, A. V. Amelin, А. A. Artamonov

    One of the key mediator systems involved in the pathogenesis of migraine is the serotonergic system, which led to the development and introduction of serotonin 5-HT1 receptor agonists (triptans) into clinical practice as the most important means of preventing migraine attacks. Serotonin 5-HT1 receptor agonists have a high selectivity for the 5-HT1B and 5-HT1D receptor subtypes, which ensures their effect on the pathogenesis of migraine attack development.Objective: to evaluate the efficacy of a standard dose of Relonova in the relief of four moderate to severe migraine attacks in outpatients in reallife clinical practice, including assessment of the rate of attack relief, the effect of the drug on headache intensity, concomitant symptoms and the general condition of the patient.Material and methods. The study involved 415 patients with migraine (319 women and 96 men; mean age 35.7±7.8 years). A total of 1660 migraine attacks were analyzed. The average number of migraine days per month was 6.72±3.99. Migraine attacks with aura were observed in 125 patients (30.1%). Patients stopped four migraine attacks and filled out self-monitoring diaries. Treatment efficacy was assessed according to the European Headache Federation (EHF) Consensus Algorithm for Determining Effective Treatment of a Migraine Attack.Results. After taking Relonova, pain became mild or disappeared completely in 30 minutes in 52% of patients, in 76% in 1 hour, in 93% in 2 hours, in 99% in 4 hours and in 99% of patients in 24 hours. A recurrence of the headache occurred in 8.8% of the attacks. Additional analgesic treatment after 30 minutes was required in 14% of cases, after which period the frequency did not exceed 2%. Adverse events were observed in 4% of patients and were mild. The overwhelming majority (90%) of study participants were able to successfully terminate three attacks and were responders.Conclusion. Relonova is an effective and safe agent to stop migraine attack and can be recommended for use in daily clinical practice.


  • Open Access

    Alternative and complementary treatments for migraine

    by G. R. Tabeeva, E. G. Filatova, A. V. Amelin, V. V. Osipova, A. R. Artemenko, L. R. Akhmadeeva, E. V. Ekusheva, M. I. Koreshkina, E. R. Lebedeva, A. V. Sergeev, et al.

    Migraine is a chronic neurological disorder that is associated with considerable disadaptive effect on patients. Despite the development of pharmacotherapy strategies for migraine, only one third of patients are satisfied with their overall treatment. Many migraine patients turn to complementary and alternative medicine (CAM), which is not usually considered a part of conventional medicine and is not always evidence-based. In practise, however, they are often used to improve the effectiveness of standard therapy or to provide alternative treatment. In addition, in CAM methods, the patient is actively involved in the choice of treatment strategies, and they have good adherence. The basic principles and approaches of CAM are increasingly being introduced into clinical practise. This review discusses the principles of CAM in the treatment of migraine as a holistic approach using lifestyle strategies and selected non-pharmacological treatments that have been shown to be effective and rational.


  • Open Access

    Efficacy of zolmitriptan nasal spray in adult patients with migraine

    by A. V. Amelin, I. S. Vaganova, M. I. Koreshkina, N. M. Tereshchenko

    Introduction. Migraine is a common disabling condition. Migraine patients require fast-acting drugs with high efficacy. Prior studies have demonstrated that zolmitriptan oral dosage forms (oral tablets) are highly effective in the treatment of migraine attacks.Aim. To evaluate the efficacy, timing of onset of therapeutic effect and tolerability of zolmitriptan nasal spray (Xsenza®) in the treatment of migraine.Materials and methods. A total of 39 patients aged 20 to 58 years with migraine were enrolled in a prospective, multicentre, observational study. Patients were included in a group to treat three consecutive migraine attacks with zolmitriptan nasal spray at a dose of 2.5 mg according to their habitual behaviour model that most closely reflects clinical practice. Efficacy endpoint (positive attack treatment outcome) was the generally accepted measure of reduction in cephalalgia intensity and concomitant autonomic symptoms (reduction in pain and autonomic symptoms from severe/moderate to mild/absence severity according to VAS) 2 hours after zolmitriptan inhalation.Results. The absence or mild intensity of headache was reported in 25% of patients 10 minutes (earliest assessment in that study) and in 28% of patients 30 minutes after administration of the drug. The proportion of patients with positive treatment outcomes in all three consecutive migraine attacks two hours after administration of zolmitriptan nasal spray 2.5 mg was 69.2%, 75% and 75%, respectively. Zolmitriptan nasal spray was well tolerated, while most adverse events were mild in severity and transient in nature.Conclusions. Zolmitriptan nasal spray (Xsenza®) is highly effective in the treatment of migraine attacks and has a rapid onset of action. The drug combines high efficacy and good tolerability.


  • Open Access

    Optimization of migraine attacks relief

    by G. R. Tabeeva, A. V. Amelin, L. R. Akhmadeeva, A. B. Danilov, O. B. Doronina, M. I. Koreshkina, N. V. Latysheva, E. G. Mendelevich, I. V. Sarvilina, A. V. Sergeev, et al.

    On December 24, 2022, in Moscow an interdisciplinary Council of Headache Experts, held under the auspice of the interregional public organization “Russian Society for the Study of Headache”, discussed the key problems of effective treatment of a migraine attack and the possibilities of a specific drug Kaporiza® (rizatriptan). Despite the development of strategies for the relief of migraine attacks and the effectiveness of triptans as first-line therapy, the choice of a specific drug in accordance with the individual clinical profile of the patient is difficult due to the existence of drugs in various forms (standard tablets, oral dispersible forms, injections, nasal sprays, rectal suppositories). Rizatriptan in the form of an orally dispersible tablet (ODT) has a number of advantages: high bioavailability, fast onset of action, and ease of use. Therefore, Kaporiza® (rizatriptan ODT) may be recommended as a priority therapy for all migraine patients who prefer the dispersible tablet form and who experience symptoms of nausea and vomiting, as well as for patients who have experience of poor efficacy and/or poor tolerability of other triptans. The Expert Council recommends to include rizatriptan ODT in the next edition of the clinical guidelines for the diagnosis and treatment of migraine as a first-line agent with Level A evidence.


  • Open Access

    Evaluation and treatment of medication-overuse headache: Russian experts’ guidelines

    by G. R. Tabeeva, V. V. Osipova, E. G. Filatova, Yu. E. Azimova, A. V. Amelin, A. R. Artyomenko, Yu. D. Vorobyeva, E. V. Ekusheva, M. I. Koreshkina, E. R. Lebedeva, et al.

    The Russian experts’ guidelines on evaluation and treatment of medication-overuse headache are based on evidence-based medicine, the latest revision of the International Classification of Headache Disorders. Basic information about epidemiology, risk factors, pathophysiological mechanisms, evaluation, and the most effective pharmacological drug and non-pharmacological approaches to managing patients with medication-overuse headache are presented.


  • Efficacy and safety of transcranial magnetic therapy in patients with migraine in clinical practice

    by M.I. Koreshkina, A.B. Danilov, A.A. Kiselevich, A.K. Nepomilueva, E.I. Parkaeva, E.A. Shestel, A.E. Chernousova

    Мигрень — это хроническое заболевание, сопровождающее человека на протяжении десятилетий и влияющее не только на здоровье, но и на его социально-экономический статус. Магнитотерапия вошла в рекомендации по лечению мигрени, ее проводят как для купирования приступов, так и в виде профилактических курсов с целью уменьшения интенсивности и количества мигренозных атак. Проведено мультицентровое двойное слепое рандомизированное исследование эффективности применения магнитотерапии для лечения частых приступов эпизодической мигрени. В основную группу вошли 27 пациентов с мигренью без ауры, в группу контроля — 13 пациентов с мигренью без ауры. По результатам исследования можно сделать вывод о положительном влиянии магнитотерапии на течение мигрени: об уменьшении частоты приступов и количества дней с применением препаратов для купирования приступов, о снижении и выраженности тревоги и депрессии.

  • Diagnosis and Treatment of Migraine: Recommendations of Russian Experts

    by V. V. Osipova, E. G. Filatova, A. R. Artemenko, E. R. Lebedeva, Yu. E. Azimova, N. V. Latysheva, A. V. Sergeev, A. V. Amelin, M. I. Koreshkina, K. V. Skorobogatykh, et al.


  • Open Access

    Ways of optimizing the management of patients with migraine in Russia (resolution of the council of experts)

    by G. R. Tabeeva, A. V. Amelin, L. R. Akhmadeeva, A. B. Danilov, O. B. Doronina, M. I. Koreshkina, O. V. Kurushina, V. V. Osipova, A. V. Sergeev, E. G. Filatova, et al.

    Medical article медицинская статья